DMDermot Henry Mallon

Dermot Henry Mallon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dermot Henry Mallon has a total of 217 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predicting brain tumour enhancement from non-contrast MRI with artificial intelligence: a multicohort, retrospective, diagnostic accuracy study

    by James K Ruffle, Samia Mohinta, Guilherme Pombo, Asthik Biswas, Alan Campbell, Indran Davagnanam, David Doig, Ahmed Hammam, Harpreet Hyare, Farrah Jabeen, et al.


  • Open Access

    Stroke and HIV: Emerging mechanisms and management in a changing epidemic

    by Tiwonge E Phiri, Kathryn B Holroyd, Shannon A Bernard Healey, Dermot H Mallon, Laura A Benjamin

    Background: Stroke is increasingly recognized as an important cause of morbidity and mortality in people living with HIV (PLWH). Although advances in antiretroviral therapy (ART) have transformed HIV into a chronic condition, cerebrovascular complications remain common and often underrecognized. Aims: This review summarized current understanding of the pathogenesis, clinical features, investigations, and management of stroke in PLWH, highlighting knowledge gaps and priorities for future research. Summary of evidence: HIV-associated stroke is multifactorial. Mechanisms include HIV-associated vasculopathy, opportunistic infections, immune reconstitution inflammatory syndrome (IRIS), and traditional vascular risk factors accelerated by HIV and ART. Clinical presentations may resemble those in HIV-negative individuals but occur at a younger age, with distinct subtype distributions and a higher frequency of concomitant infection. Investigation requires a tiered approach: standard stroke imaging and cardiac work-up, supplemented by cerebrospinal fluid analysis and advanced vessel wall imaging in patients with suspected inflammatory or infectious etiology. Reperfusion therapies appear feasible in stable HIV disease, but evidence remains limited. Outcomes are shaped by immune status, access to care, and comorbidities, with higher recurrence and cognitive decline reported in several cohorts. Real-world challenges include stigma, clinician awareness gaps, and inequities in diagnostics and treatment, particularly in low-resource settings. Conclusions: Stroke in PLWH is an emerging global health challenge. Clinicians should maintain a high index of suspicion in younger patients and those with advanced disease or recent ART initiation. Multidisciplinary care pathways and equitable access to diagnostics and secondary prevention are essential. Future research must address unresolved questions around vasculopathy, IRIS, small vessel disease, and long-term cognitive outcomes to guide evidence-based management.


  • Open Access

    Novel treatment of enterovirus encephalitis associated with B-cell depleting therapy

    by H.M.W. Bestwick, A.E. Corrigan, A. Baheerathan, C.F. Houlihan, D.H. Mallon, J. Spillane, D.T. Chard, S.A. Trip, R.L. Brown, J. Breuer


  • Open Access

    Clinical–Radiological Spectrum of Cerebral Amyloid Angiopathy‐Related Inflammation

    by Larysa Panteleienko, Gargi Banerjee, Dermot Mallon, Kitti Thiankhaw, Rupert Oliver, Victoria Harvey, Gareth Ambler, Michael Zandi, Hans Rolf Jäger, David J. Werring

    Objective: To identify clinical and radiological features of cerebral amyloid angiopathy‐related inflammation (CAA‐ri), and compare these features with those of sporadic CAA, to improve the understanding, diagnosis, and clinical care of CAA‐ri. Methods: We retrospectively reviewed routine clinical data from 37 patients with CAA‐ri and 158 patients with sporadic CAA, including conventional vascular risk factors and comorbidities. We assessed brain magnetic resonance imaging for: radiological markers of CAA; features of amyloid‐related imaging abnormalities with edema/effusion (ARIA‐E) including parenchymal white matter hyperintensities, sulcal hyperintensities, and gyral swelling; and evidence of neurodegeneration (medial temporal atrophy and global cortical atrophy). Results: Compared with patients with sporadic CAA, patients with CAA‐ri had more numerous lobar cerebral microbleeds (median 207[IQR 33‐811] vs 19[IQR 7‐58], p < 0.001), and higher rates of medial temporal and global cortical atrophy. In comparison with sporadic CAA, all ARIA‐E features were much more common in patients with CAA‐ri (parenchymal hyperintensities 89% vs 3%, sulcal hyperintensities 78% vs 9%, and gyral swelling 86% vs 0.6%), as were conventional vascular risk factors (hypertension, dyslipidemia) and long‐term comorbidities (inflammatory and infectious disorders, autoimmune or connective tissue disorders, or malignancies). Interpretation: Features of ARIA‐E (parenchymal white matter hyperintensities, sulcal hyperintensities, and gyral swelling) are more common in CAA‐ri in comparison with “non‐inflammatory” sporadic CAA, suggesting shared mechanisms with Alzheimer's disease immunotherapy and a potential role in improving diagnostic accuracy for CAA‐ri. The high prevalence of atrophy and lobar cerebral microbleeds suggests a potential mechanistic role for capillary CAA, Alzheimer's disease, or both, in CAA‐ri. Cardiovascular risk factors and other long‐term comorbidities may also be relevant to the underlying mechanisms of CAA‐ri. ANN NEUROL 2026;99:148–158


  • Open Access

    Association of Intracranial Dolichoectasia and Cerebral Small Vessel Disease in Patients With Intracerebral Hemorrhage

    by Kitti Thiankhaw, Larysa Panteleienko, Catriona R. Stewart, Rupert Oliver, Dermot Mallon, Gareth Ambler, David J. Werring

    Background: Intracranial arterial dolichoectasia (IADE) is associated with cerebral small vessel disease (CSVD) in populations with ischemic stroke. Whether IADE is related to CSVD markers in patients with intracerebral hemorrhage (ICH) is unclear but might be relevant for CSVD diagnosis and prognosis. We aimed to investigate the prevalence and associations of IADE in patients with ICH. Methods: We included consecutive patients with ICH between February 2016 and September 2023. IADE was determined using magnetic resonance angiography based on validated scales assessing vessel diameter, length, and tortuosity. Neuroimaging markers of CSVD were investigated using validated magnetic resonance imaging rating scales. Left ventricular mass (LVM) was determined from transthoracic echocardiography. Multivariable binary logistic regression analyses were used to evaluate associations between IADE and CSVD. Results: We included 138 patients with a mean age of 66.7±11.8 years, 58.0% men. IADE was present in 16 patients (11.6%). LVM was greater in patients with IADE (183.0±61.3 g versus 155.3±51.2 g, P =0.04). Patients with ICH and IADE had significantly higher proportions of deep lacunes (43.8% versus 18.0%, P =0.02) and deep cerebral microbleeds (56.3% versus 27.1%, P =0.02) compared with individuals without IADE. IADE was independently associated with deep lacunes (adjusted odds ratio [OR], 3.10 [95% CI, 1.02–9.55], P =0.04), severe periventricular white matter hyperintensities (adjusted OR, 3.29 [95% CI, 1.00–10.94], P =0.04), and deep cerebral microbleeds (adjusted OR, 2.80 [95% CI, 1.04–8.65], P =0.04). Among these CSVD markers, IADE had a high predictive value for deep cerebral microbleeds with a receiver operating characteristic curve of 0.75 (95% CI, 0.66–0.85). There was no statistically significant association between IADE and lobar ICH (adjusted OR, 1.29 [95% CI, 0.36–4.64], P =0.70) or cerebral amyloid angiopathy (adjusted OR, 0.46 [95% CI, 0.13–1.67], P =0.24). Conclusions: IADE is found in approximately 12% of patients with ICH and is independently associated with neuroimaging markers of arteriolosclerosis but not cerebral amyloid angiopathy.


  • Open Access

    Cerebral Amyloid Angiopathy‐Related Inflammation in Iatrogenic Cerebral Amyloid Angiopathy

    by Larysa Panteleienko, Dermot Mallon, Cho Me Me Htet, Nathaniel Lizak, Michael Zandi, Gargi Banerjee, David J. Werring

    Introduction: Cerebral amyloid angiopathy (CAA) related inflammation (CAA‐ri) is considered to be a distinct syndrome caused by an inflammatory response to amyloid‐β deposition in the walls of small leptomeningeal and cortical vessels in patients with sporadic CAA. However, recent data suggest that inflammation might contribute to a broader range of CAA subtypes.Results: We describe a case of probable iatrogenic CAA (iCAA), which manifested with multiple intracerebral haemorrhages complicated by the development of clinical and radiological features of CAA‐ri, which responded to steroids. Clinical, neuroimaging and CSF data suggested possible co‐existing Alzheimer's pathology.Discussion: CAA‐ri may occur in association with iCAA, suggesting that a broader spectrum of patients might benefit from steroid treatment than previously assumed.


  • Open Access

    Sulcal Hyperintensity as an Early Imaging Finding in Cerebral Amyloid Angiopathy–Related Inflammation

    by Larysa Panteleienko, Gargi Banerjee, Dermot Henry Mallon, Victoria Harvey, Rupert Oliver, Gary Hotton, William Knight, Sayan Datta, Michael S. Zandi, Hans Rolf Jäger, et al.

    Cerebral amyloid angiopathy-related inflammation (CAA-ri) is a subtype of CAA with distinct clinical and radiologic features. Existing diagnostic criteria require the presence of characteristic asymmetrical white matter hyperintensity (WMH), together with classical hemorrhagic neuroimaging markers of CAA. There are limited data for other diagnostic neuroimaging markers of CAA-ri. This is a case series from a specialist hospital intracerebral hemorrhage service. We describe 4 patients with CAA-ri who had regions of sulcal hyperintensity, with or without gyral swelling at clinical presentation, but did not fulfill current diagnostic criteria because of the absence of typical asymmetric WMH on brain MRI. All 4 patients were subsequently diagnosed with CAA-ri; three later developed asymmetric WMHs with disease relapse, and 2 had pathologically proven CAA-ri; 1 patient had both. Regions of sulcal hyperintensity, sometimes with associated gyral swelling, can be an early imaging finding in CAA-ri. These neuroimaging markers could potentially improve the accuracy of existing diagnostic criteria for CAA-ri to allow earlier diagnosis and treatment without biopsy in patients with atypical presentations.


  • Open Access

    Validation of the 2023 International Diagnostic Criteria for MOGAD in a Selected Cohort of Adults and Children

    by James A. Varley, Dimitrios Champsas, Timothy Prossor, Giuseppe Pontillo, Omar Abdel-Mannan, Zhaleh Khaleeli, Axel Petzold, Ahmed T. Toosy, Sachid A. Trip, Heather Wilson, et al.

    To test the performance of the 2023 myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) criteria in adults and children with inflammatory demyelinating conditions who were tested for MOG antibodies (Abs). This was a retrospective study of patients tested for MOG-Abs from 2018 to 2022 in 2 specialist hospitals. The inclusion criteria comprised ≥1 attendance in an adult or pediatric demyelinating disease clinic and complete clinical and MRI records. The final clinical diagnosis of MOGAD, made by the treating neurologist, was taken as the benchmark against which the new criteria were tested. The international MOGAD diagnostic criteria were applied retrospectively; they stipulate at least 1 clinical or MRI supporting feature for MOGAD diagnosis in positive fixed MOG cell-based assay without a titer. The performance MOG-Ab testing alone for MOGAD diagnosis was also assessed and compared with that of MOGAD criteria using the McNemar test. Of the 1,879 patients tested for MOG-Abs, 539 (135 pediatric and 404 adults) met the inclusion criteria. A clinical diagnosis of MOGAD was made in 86/539 (16%) patients (37 adults, 49 children), with a median follow-up of 3.6 years. The MOGAD diagnostic criteria had sensitivity of 96.5% (adults 91.9%, children 100%), specificity of 98.9% (adults 98.8%, children 98.9%), positive predictive value of 94.3% (adults 89.4%, children 98%), negative predictive value of 99.3% (adults 99.2%, children 100%), and accuracy of 98.5% (adults 98.3%, children 99.2%). When compared with MOG-Ab testing alone, a difference was seen only in adults: a significantly higher specificity (98.9% vs 95.6%, p = 0.0005) and nonstatistically significant lower sensitivity (91.9% vs 100%, p = 0.08). The international MOGAD diagnostic criteria exhibit high performance in selected patients with inflammatory demyelinating diseases (who had a high pretest probability of having MOGAD) compared with best clinical judgment; their performance was better in children than in adults. In adults, the MOGAD criteria led to an improvement in specificity and positive predictive value when compared with MOG-Ab testing alone, suggesting that the requirement of at least 1 clinical or MRI supporting feature is important. Future work should address the generalizability of the diagnostic criteria to cohorts of greater clinical diversity seen within neurologic settings.


  • Open Access

    Iatrogenic cerebral amyloid angiopathy in older adults

    by Larysa Panteleienko, Dermot Mallon, Rupert Oliver, Ahmed Toosy, Yuki Hoshino, Aya Murakami, Kanishk Kaushik, Marieke J. H. Wermer, Hideo Hara, Yusuke Yakushiji, et al.

    Background and purpose: An increasing number of cases of iatrogenic cerebral amyloid angiopathy (CAA) have now been reported worldwide. Proposed diagnostic criteria require a history of medical intervention with potential for amyloid‐β transmission, for example those using cadaveric dura mater or requiring instrumentation of the brain or spinal cord. Clinical presentation occurs after an appropriate latency (usually three or four decades); to date, most patients with iatrogenic CAA have had ‘early‐onset’ disease (compared to sporadic, age‐related, CAA), as a consequence of childhood procedures.Results: We describe five cases of possible iatrogenic CAA in adults presenting in later life (aged 65 years and older); all had prior neurosurgical interventions and presented after a latency suggestive of iatrogenic disease (range 30–39 years). Use of cadaveric dura mater was confirmed in one case, and highly likely in the remainder.Conclusion: The presentation of iatrogenic CAA in older adults widens the known potential spectrum of this disease and highlights the difficulties of making the diagnosis in this age group, and particularly in differentiating iatrogenic from sporadic CAA. Increased vigilance for cases presenting at an older age is essential for furthering our understanding of the clinical phenotype and broader implications of iatrogenic CAA.


  • Open Access

    Real-world evaluation of Brainomix e-Stroke software

    by Dermot Mallon, Matthew Fallon, Eirini Blana, Cillian McNamara, Arathi Menon, Chak Lam Ip, Jack Garnham, Tarek Yousry, Peter Cowley, Robert Simister, et al.

    Background and purpose Brainomix e-Stroke is an artificial intelligence-based decision support tool that aids the interpretation of CT imaging in the context of acute stroke. While e-Stroke has the potential to improve the speed and accuracy of diagnosis, real-world validation is essential. The aim of this study was to prospectively evaluate the performance of Brainomix e-Stroke in an unselected cohort of patients with suspected acute ischaemic stroke. Methods The study cohort included all patients admitted to the University College London Hospital Hyperacute Stroke Unit between October 2021 and April 2022. For e-ASPECTS and e-CTA, the ground truth was determined by a neuroradiologist with access to all clinical and imaging data. For e-CTP, the values of the core infarct and ischaemic penumbra were compared with those derived from syngo.via, an alternate software used at our institution. Results 1163 studies were performed in 551 patients admitted during the study period. Of these, 1130 (97.2%) were successfully processed by e-Stroke in an average of 4 min. For identifying acute middle cerebral artery territory ischaemia, e-ASPECTS had an accuracy of 77.0% and was more specific (83.5%) than sensitive (58.6%). The accuracy for identifying hyperdense thrombus was lower (69.1%), which was mainly due to many false positives (positive predictive value of 22.9%). Identification of acute haemorrhage was highly accurate (97.8%) with a sensitivity of 100% and a specificity of 97.6%; false positives were typically caused by areas of calcification. The accuracy of e-CTA for large vessel occlusions was 91.5%. The core infarct and ischaemic penumbra volumes provided by e-CTP strongly correlated with those provided by syngo.via (ρ=0.804—0.979). Conclusion Brainomix e-Stroke software provides rapid and reliable analysis of CT imaging in the acute stroke setting although, in line with the manufacturer’s guidance, it should be used as an adjunct to expert interpretation rather than a standalone decision-making tool.